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Abst rac t
Introduction: The tumor necrosis factor (TNF-α) was initially described as lymphotoxin or cachectin. The discovery 
of therapies blocking the action of TNF-α, in 1988, started a new era in the therapy. One of often reported adverse 
effects related to the use of TNF-α antagonists is induction of the formation of autologous antibodies and antibod-
ies neutralizing anti-TNF drugs. The development of anti-TNF-induced lupus or classical drug-induced lupus is more 
rarely reported.
Aim: To evaluate the presence and the level of anti-nuclear antibodies in patients with psoriasis and psoriatic ar-
thritis and the influence of anti-TNF therapy used on the concentration of antinuclear antibody (ANA).
Material and methods: A total of 28 subjects were included in the study. 71.4% of subjects were diagnosed with 
psoriatic arthritis and 28.6% with plaque psoriasis.
Results: Among the patients with plaque psoriasis, the antinuclear antibodies were found in 25% of subjects and 
in 80% of patients with psoriatic arthritis. After the treatment an increase in the titer or appearance of antibodies 
was found in 66.7% in the infliximab group, 18.2% in the etanercept group and 54.7% in the adalimumab group. No 
subjects developed symptoms of drug-induced systemic lupus.
Conclusions: Our findings have shown that all anti-TNF therapies induced ANA in psoriatic arthritis and psoriatic 
patients. Considering a mild course of lupus induced by anti-TNF treatment and, usually intrinsic, resolution of 
symptoms, the biological therapy still appears as a safe treatment for patients.
Key words: anti-tumor necrosis factor therapy, psoriasis, psoriatic arthritis, anti-tumor necrosis factor-induced 
lupus, drug-induced lupus.
Introduction
The tumor necrosis factor α (TNF-α) was initially 
described as lymphotoxin or cachectin. It has been sug-
gested that the substance may cause cachexia [1–3]. Ac-
cording to the current state of knowledge, it is one of 
cytokins, or protein substances participating in inflam-
matory reaction and immune response of the body. It has 
been licensed for a variety of inflammatory conditions in-
cluding psoriasis, psoriatic arthritis, rheumatoid arthritis, 
ankylosing spondylitis, Crohn’s disease, and ulcerative 
colitis. The discovery of therapies blocking the action of 
TNF-α, in 1988, started a new era in the therapy of the 
diseases mentioned above. Currently in the European 
Union, including Poland, three drugs from this group are 
authorized: infliximab, etanercept and adalimumab for 
psoriasis and psoriatic arthritis treatment [4].
Infliximab is a recombined, chimeric, mouse-derived, 
monoclonal antibody against TNF-α cytokine, containing 
an Fc fragment of human IgG immunoglobulin and vari-
able chains of IgG1k class [5]. Infliximab neutralizes the 
biological activity of TNF-α by binding the soluble TNF-α 
(monomers and trimers) and the TNF-α bound with the 
cell membrane [6]. On the other hand, it does not bind 
TNF-β. It shows a capacity for the mediation of the ly-
sis of cells showing the expression of TNF-α (peripheral 
monocytes, macrophages, neutrophils) by cytotoxicity 
dependent on the complement or on the antibodies. 
The drug is administered in an IV infusion, according to 
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Summary of Product Characteristics (SPC) in the course 
of psoriatic arthritis at a dose of 5 mg/kg b.w. Next time it 
is administered also at 5 mg/kg b.w., after 2 and 6 weeks, 
and then every 8 weeks. This drug is highly effective – 
a reduction of Psoriasis Area Severity Index (PASI) by 75% 
(PASI-75) is obtained in about 80% of patients treated 
with the recommended dose [4].
Etanercept is a fusion protein consisting of two sub-
units: a membrane subunit p75 of the TNF-α receptor 
and a Fc part of IgG1 immunoglobulin [5]. It binds two 
molecules of TNF-α, acting as a false receptor. Moreover, 
it binds TNF-β [6]. The drug is administered sub-cuta-
neously, at a dose of 2 times of 25 mg/week or once, 
50 mg/week [4]. The effectiveness of treatment (PASI-75) 
is evaluated at about 40% after 12 weeks of therapy. 
The effectiveness could be increased by using a dose 
two times larger (i.e. 2 times 50 mg/week) in the first 
3 months of therapy. Etanercept is the only biological 
drug admitted for use in the ordinary psoriasis treatment 
in children. 
Adalimumab is the first fully human monoclonal anti-
body IgG1k, against the TNF-α cytokine [5]. Adalimumab 
selectively neutralizes TNF-α, inhibiting its binding to p55 
and p75 receptors [6]. Adalimumab is administered sub-
cutaneously, with an initial dose of 80 mg, then 40 mg 
a week, and next, 40 mg every 2 weeks in maintenance 
therapy. The effectiveness of adalimumab in the first 
16 weeks of treatment, evaluated with PASI-75 index, is 
53–80%. The treatment with adalimumab allows to reach 
and maintain PASI-75 in 60% of patients treated during 
60 weeks [4].
The most often reported adverse effects related to 
the use of TNF-α antagonists are: activation of opportune 
infections, including Mycobacterium tuberculosis, demy-
elinating diseases, congestive heart failure, induction of 
the formation of autologous antibodies and antibodies 
neutralizing anti-TNF drugs [7]. The development of anti-
TNF-induced lupus (ATIL) or classical drug-induced lupus 
(DIL) is more rarely reported.
Aim 
The aim of the work is to evaluate the presence and 
level of anti-nuclear antibodies in patients with psoria-
sis and psoriatic arthritis and the influence of anti-TNF 
therapy used (infliximab, etanercept and adalimumab) 
on the concentration of antinuclear antibodies (ANA) in 
patients treated at the Dermatology Clinic of the Jagiel-
lonian University Medical College (UJCM). 
Material and methods
A total of 28 subjects were included in the study: 
19 men and 9 women, aged 19–67 (mean age 43.7). In the 
analyzed group, 71.4% of subjects (20/28) were diagnosed 
with psoriatic arthritis (according to Caspar criteria) and 
28.6% (8/28) were diagnosed with plaque psoriasis. Six 
patients were treated with infliximab in a due dose, 
for 7 months on average. Eleven patients were given 
etanercept (50 mg s.c./week) during 6–48 months (25.5 
on average). Eleven patients were given adalimumab 
(40 mg s.c./14 days) during 12–36 months (21 on aver-
age). The presence and levels of ANA were evaluated be-
fore and after treatment. The type of luminescence and 
the titer were determined by indirect immunofluores-
cence on Hep-2 cells, using anti-human IgG labeled with 
fluorescein. Dilutions of 1/160 and higher were consid-
ered as positive. The antibodies against soluble antigens: 
anti-Ro, anti-La, anti-Scl70, anti-Jo1, anti-uRNP, anti-Sm 
were evaluated by the ELISA method.
Statistical analysis
The obtained results were processed with statistical 
analysis. 
Results
In the studied group, the antinuclear antibodies were 
found, before the inclusion of biological treatment, in 
53.6% of subjects (15/28), in the remaining subjects the 
ANA were not found (46.4%; 13/28 subjects). Among 
the patients with positive antibodies, the following ti-
ters were observed: 1/160 in 7 (25%) subjects, 1/320 in 
5 (17.9%), 1/640 in 1 (3.6%), and 1/1280 in 2 (7.1%) pa-
tients. The distribution of levels of individual antibodies 
depending on the subjects’ sex is presented in Table 1. No 
significant differences in mean age (p = 1.01) and gender 
(p = 0.73) were observed when the patients who became 
ANA-positive during the treatment were compared to pa-
tients who remained persistently ANA-negative.
Among the patients with plaque psoriasis, antinucle-
ar antibodies were found in 25% of subjects (2/8) and in 
80% of patients with psoriatic arthritis (16/20) (Figure 1).
In the group of patients treated with infliximab, the 
antinuclear antibodies were confirmed in 33.3% (2/6) 
before starting the treatment. After the treatment, an in-
crease in the titer or appearance of antibodies was found 
in 66.7% (4/6), in one subject the ANA titer decreased. 
Overall, after the treatment, the ANA were observed in 
83.3% (5/6) (Figure 2).
Table 1. The titer of antibodies depending on the 
subjects’ sex
Titer Percentage of subjects
(n = 28)
Percentage 
of women
Percentage 
of men
1/160 7/28 (25%) 1/28 (3.6%) 6/28 (21.4%)
1/320 5/28 (17.9%) 1/28 (3.6%) 4/28 (14.3%)
1/640 1/28 (3.6%) 1/28 (3.6%) 0/28 (0%)
1/1280 2/28 (7.1%) 1/28 (3.6%) 1/28 (3.6%)
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In the group of patients treated with etanercept, the 
ANA were confirmed in 63.6% (7/11) before starting the 
treatment. After the treatment, an increase in the titer 
or appearance of antibodies was found in 18.2% of sub-
jects. In 63.8% of patients the level of ANA maintained 
constant. After the treatment, the ANA were observed in 
90.9% (10/11) (Figure 3).
In the group of patients treated with adalimumab, the 
ANA were confirmed in 63.6% (7/11) before starting the 
treatment. After the treatment, an increase in the titer of 
ANA was observed in 27.3% of patients, the generation 
of antibodies was found in 27.3% (3/11) of studied sub-
jects. In the remaining patients, the level of antibodies 
maintained constant. After the treatment, the ANA were 
observed in 90.9% (10/11) (Figure 4).
The antibodies against soluble antigens: anti-Ro, 
anti-La, anti-Scl70, anti-Jo1, anti-uRNP, anti-Sm were not 
found in any patients.
No subjects developed symptoms of drug-induced 
systemic lupus.
Discussion
The first clinical trials with infliximab in the therapy 
of rheumatoid arthritis have already shown that the for-
mation of ANA during the treatment is possible (ANA in 
29–76.7% of patients, anti-dsDNA in 10–29%) [8]. In pa-
tients treated with other anti-TNF drugs, the frequency 
of generating antibodies is lower, but also proven. During 
the therapy with etanercept it is evaluated at 11–36% and 
5–15%, respectively, and with adalimumab – 12.9% and 
5.3%. In the studied group, the percentage of patients 
with newly generated antibodies against the components 
of the cell’s nucleus was similar [8].
Atzeni et al. claim that the increase in the auto-anti-
body level after the anti-TNF treatment varies, depend-
Figure 1. Antinuclear antibodies among the patients with 
psoriasis and psoriatic arthritis before anti-TNF treatment
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Figure 2. Antinuclear antibodies in the group of patients 
treated with infliximab
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Figure 3. Antinuclear antibodies in the group of patients 
treated with etanercept
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Figure 4. Antinuclear antibodies in the group of patients 
treated with adalimumab
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ing on the primary disease, and it is higher in patients 
with spondyloarthropathy, despite the fact that initially, 
in non-treated patients, ANA were found more frequently 
in the group with rheumatoid arthritis [9]. However, the 
results of other authors do not support these claims [10].
Currently one work documenting the frequency of 
ANA generation in patients with psoriatic arthritis, treat-
ed with anti-TNF drugs, is available in the PubMed base. 
Among the above patients, the incidence of generation of 
auto-antibodies is estimated at 47.8% [11]. Homogenous 
and granulated patterns dominate. Williams et al. state 
that new antibodies against the double-stranded DNA 
are usually generated in IgM and IgA classes, which are 
considered as non-pathogenic [10]. Anti-dsDNA appear 
even after a short-term therapy (6 weeks), however, in 
a long-term observation of patients, no conversion of 
these antibodies into class IgG, pathognomonic for SLE, 
was reported [5]. Despite an increase in the antibody lev-
el, patients usually respond well to the biological treat-
ment [12]. Lora et al. did not observe differences in pso-
riasis intensity, measured by PASI scale, in ANA(+) and 
ANA(–) patients [13]. Nevertheless, some authors report 
a lower effectiveness of drugs from the anti-TNF group in 
patients with the presence of anti-dsDNA [14]. Among the 
patients generating high levels of antibodies against sin-
gle-stranded DNA (ssDNA) in the IgG class, an increased 
percentage of therapy interruptions due to allergic skin 
reactions or general anaphylaxis is reported [15].
It is considered that the generation of autoantibod-
ies during anti-TNF therapy is related to the induction of 
humoral response due to an inhibition of the response 
of cytotoxic T-lymphocytes, which in physiological con-
ditions inhibits the reactivity of B-lymphocytes [16]. 
A hypothesis of the so-called “cytokine shift” is also 
suggested: the TNF blockers reduce the production of 
cytokines by Th1 lymphocytes and therefore they shift 
the immunologic response towards cytokines IL-10 and 
IFN-α, produced by Th2 lymphocytes [17]. Systemic in-
hibition of the TNF-α activity may affect the apoptosis, 
weakening the expression of CD44. It leads to a reduction 
in removing, by phagocytes, the cellular waste (nuclear 
material) left after apoptosis, and therefore it promotes 
the production of autoantibodies against DNA and other 
nuclear antigens [18].
Drug-induced lupus is the most often reported in the 
therapy with procainamide (20%) and hydralazine (5–
8%) [19]. Among the patients treated with the biological 
drug, the incidence of anti-TNF-induced lupus is estimat-
ed at 0.19% among the patients receiving infliximab and 
0.18% of patients treated with etanercept [20]. The Brit-
ish Society of Rheumatology (BSR) Biologic Register in-
cludes 11394 subjects. In the described group, 40 patients 
have developed symptoms of lupus induced by anti-TNF 
therapy (cutaneous or full-blown ATIL). The control group 
comprises the patients treated with DMARDs (disease-
modifying antirheumatic drugs): lupus was observed 
in 1 patient [10]. The American researchers note impor-
tant differences in the antibody profile between patients 
that developed DIL and ATIL. The classical drug-induced 
lupus strongly correlates with ANA (> 99%) and anti-
histone antibodies (> 95%); anti-dsDNA are usually ab-
sent. The antibody profile of ATIL patients concerns anti-
dsDNA (> 90%) and anti-histone antibodies (57%) [10]. 
Additionally, cutaneous symptoms are much more often 
observed in ATIL (72% compared to DIL 9–27%) [21, 22]. 
Systemic symptoms typical of systemic lupus occur with 
a similar frequency in both groups. 
Currently there is no standard recommendation as 
to ATIL prevention. In the literature, single observations 
on reducing the frequency of the generation of new au-
toantibodies after including DMARDs in the therapy are 
available. The preferred treatment for ATIL is the inter-
ruption of anti-TNF therapy, which usually leads to the 
resolution of symptoms [23]. A Spanish group of authors, 
conducting the research on biological therapies in au-
toimmune diseases (BIOGEAS), reports a resolution of 
symptoms of lupus induced by anti-TNF drugs in 94% 
of patients. In the studied group, 40% received glucocor-
ticoids (GCs) treatment, and 12% received an additional 
immunosuppression (MTX, LEF, AZA, MMF, CP) [18]. On 
the other hand, the British Rheumatology Society sug-
gests discontinuing anti-TNF drugs without an additional 
therapy [19].
Based on the above reports, the researchers pose 
a question about the safety of anti-TNF treatment and 
whether it should be continued if it could possibly gen-
erate serious autoimmune diseases. There are descrip-
tions of clinical cases in the literature where a transition 
of systemic lupus erythematosus into rheumatoid ar-
thritis (and vice versa) was found. Sundaramurthy et al. 
describe 893 patients with lupus, among which 7 have 
developed rheumatoid arthritis [24]. The coexistence of 
the above diseases is estimated at 0.09% of RA cases 
and is described as a separate disease, “rhupus” [25]. 
The incidences of “rhupus” and ATIL are similar, which 
allow for the presumption that some RA patients would 
have developed SLE independently of the administered 
therapy [10].
Discontinuation of the therapy with one of anti-TNF 
drugs due to development of drug-induced lupus (ATIL) 
does not disqualify the patient from this treatment 
method. It was noted that after the resolution of lupus 
symptoms, when a patient treated for Crohn’s disease or 
for rheumatoid arthritis does not meet the diagnostic cri-
teria of lupus erythematosus, inclusion of another drug 
from this group seems to be safe and possibly effective 
[26, 27].
Considering a mild course of lupus induced by anti-
TNF treatment and, usually intrinsic, resolution of symp-
toms, the biological therapy still appears as a safe treat-
ment for patients with severe psoriasis and psoriatic 
arthritis.
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